A Complete Response After Pseudo-progression: Pembrolizumab for Metastatic Squamous Cell Carcinoma (SCC) of the Bladder
Author:
Funder
Merck
Acerta
Novartis
Merrimack
Abbvie
Regeneron
Janssen
Pfizer
OmniSeq
PGDx
Publisher
Elsevier BV
Subject
Urology,Oncology
Reference34 articles.
1. Cancer statistics, 2019;Siegel;CA Cancer J Clin,2019
2. Urachal adenocarcinoma: a clinician's guide for treatment;Siefker-Radtke;Semin Oncol,2012
3. Squamous cell carcinoma of the urinary bladder: systematic review of clinical characteristics and therapeutic approaches;Martin;Arab J Urol,2016
4. Non-transitional cell bladder carcinomas;Manunta;BJU Int,2005
Cited by 4 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Challenges and opportunities in the management of non-urothelial bladder cancers;Cancer Treatment and Research Communications;2023
2. Dramatic response to pembrolizumab after pseudoprogression in a patient with advanced metastatic castration‐resistant prostate cancer;IJU Case Reports;2022-08-02
3. Unfavorable Cancer-specific Survival After Neoadjuvant Chemotherapy and Radical Cystectomy in Patients With Bladder Cancer and Squamous Cell Variant: A Multi-institutional Study;Clinical Genitourinary Cancer;2020-10
4. A Gallbladder Carcinoma Patient With Pseudo-Progressive Remission After Hydrogen Inhalation;OncoTargets and Therapy;2019-10
A Gallbladder Carcinoma Patient With Pseudo-Progressive Remission After Hydrogen Inhalation
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3